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Summary
It is often stated (hat a decrease in Von Willebrand factor (VWF),
the carrier protein of factor VIII, results in a concordant change in
factor VIII. Clinical data suggest that this is not always the case and we
hypothesized that the ratio between factor VIII and VWF depends on
the genetic defect that causes the VWF deficiency. We have analyzed
the ratio between plasma factor VIII and VWF in several subtypes of
Von Willebrand Disease and we show that the ratio is increased when
VWF synthesis is reduced, but that the ratio remains one when VWF
clearance is increased. These observations could be of clinical im-
portance äs an increased factor VIII/VWF ratio in combination with a
borderline VWF level may indicate the presence of a true genetic
defect, possibly a VWF null allele.
Introduction
Von Willebrand disease (VWD) is caused by an abnormal function
or a quantitative deficiency of the Von Willebrand factor (VWF). VWF
is an adhesive glycoprotein that circulates in plasma äs very large
multimers (1) and forms a complex with coagulation factor VIII by
noncovalent interactions to stabilize factor VIII and protect it against
degradation (2). It is often stated that a decrease in VWF, being the
carrier protein of factor VIII, results in a concordant change in the
factor VIII concentration. However, already in 1973 it was reported that
the obligatory heterozygotes in families with type 3 VWD have normal
factor VIII procoagulant activity (VIILC), despite decreased levels of
antihemophilic-factor-like antigen (later identified äs VWF) (3). From
clinical data of several subtypes of VWD we had the impression that
the ratio between factor VIII and VWF depends on the mechanism
that causes the VWF deficiency, which has never been systematically
investigated in patients with identified mutations.
The molar ratio of factor VIII to VWF (on a monomer basis) in
plasma is l :50, even though each VWF monomer contains one factor
VIII binding site (4, 5). Thus, many potential factor VIII binding sites
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on VWF are free. Concentrations of coagulation factors in plasma are
expressed in units and by definition one ml of pooled normal plasma
contains one unit of the respective coagulation factor. Therefore, the
ratio of factor VIII:C over VWF antigen (VWF:Ag) in pooled normal
plasma equals one.
To investigate the supposedly concordant changes of VWF and
factor VIII concentration, we have analyzed the ratio between plasma
factor VIII:C and VWF:Ag in several subtypes of VWD. As we were
interested in the association between the factor VIII:C/VWF:Ag ratio
and the mechanism that causes the change in VWF:Ag concentration,
we have studied only individuals for which a VWF gene mutation had
been identified. We show that the ratio of factor VIII:C/VWF:Ag is
increased when VWF synthesis is reduced, but that the ratio remains
one when VWF clearance is increased.
Materials and Methods
To evaluate the influence of different VWF gene mutations on the factor
VIII:C/VWF:Ag ratio data were collected from literature (Medline search) and
from the VWF mutations database (http://mmg2.im.med.umich.edu). As a
model for a pure quantitative VWF defect heterozygotes for VWF null alleles
(gene deletions, stop codons, frame shift mutations, splice site mutations, and
absence of mRNA) were included (6-18). Homozygotes and compound hetero-
zygotes for two VWF null alleles were not considered, äs the VWF:Ag level is
undetectably low and thus no ratio can be calculated. As representatives of
functional defects were collected: VWD type 2A mutations (restricted to the
former subtype IIA; characterized by decreased platelet-dependent function
and associated with the absence of high molecular weight multimers) (19-31),
type 2B mutations (characterized by an increased affinity for platelet glycopro-
tein Ib) (21,31-54), and type 2N mutations (characterized by a decreased factor
VIII binding affinity) (l 1,15-17,55-69). These types 2A, 2B, and 2N mutations
were included only if they had been confirmed äs causative mutation by in vitro
expression studies of the recombinant mutant VWF.
Data collected were the genetic defect, the VWF:Ag and factor VIII:C
levels, and when reported the ABO blood group and sex. Some papers reported
the mutations only and referred for clinical data to previous descriptions. In
those cases the mutation was included only, when it was possible to verify the
corresponding phenotypic data in the previous papers. In addition to these
published mutations, data were included for unpublished mutations in VWD
patients identified in our two centers (12% of all mutations analyzed in this
study). The inclusion criteria were äs for the mutations retrieved from litera-
ture. The factor VIII:C and VWF:Ag data in the carriers of VWF mutations
were compared with the factor VIII:C and VWF:Ag measurements in 301
healthy controls which came from a population-based patient-control study
(70).
Data were analyzed by ANOVA and the Student-Newman-Keuls lest was
used for multiple comparison of groups.
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Results
Complete phenotypic data on factor VIII:C and VWF:Ag levels and
genotypic data on VWF gene mutations and expression studies of
recombinant mutant VWF were found for 131 heterozygotes for VWF
null alleles, 23 heterozygotes for type 2A VWD mutations [restricted
to the former subtype IIA (71)], 81 heterozygotes for type 2B VWD
mutations, and 56 type 2N VWD mutations (29 heterozygotes, 15
homozygotes, and 12 compound heterozygotes for a null allele and a
type 2N mutation). The ABO blood group and sex were not available
for all. The factor VIILC and VWF:Ag levels, and the factor
VIII:C/VWF:Ag ratios are summarized in Figs. l and 2.
Results on Normal Controls
By definition the factor VIII:C/VWF:Ag ratio is expected to be
one in pooled normal plasma. In agreement with this the ratio in
the group of normal controls was 0.98. Although the VWF:Ag
level was significantly higher in controls with blood group non-0,
which is a well known phenomenon (72, 73), the factor VIII:
C/VWF:Ag ratio was the same for controls with either blood group 0
or non-0. In normal controls the factor VIII:C/VWF:Ag ratio was
somewhat higher in women than in man (1.01 and 0.92 respectively,
p <0.02).
Results on Null Alleles
The heterozygotes for null alleles (the model for a mere synthetic
defect of VWF) had a factor VIII:C/VWF:Ag ratio of 2.06. There was
no influence of ABO blood group or sex on the factor VIII:C/VWF: Ag
ratio. Analysis of the influence of the VWF:Ag level on the factor
VIII:C/VWF:Ag ratio showed that the ratio increased with decreasing
VWF:Ag levels" (Fig. 2): VWF:Ag >60 lU/dL, ratio 1.48; VWF:Ag
31-60 lU/dL, ratio 1.96; VWF:As 0-30 lU/dL, ratio 3.23.




n 301 129 172 16 81 29 131
Fig. l Factor VIII:C and VWF:Ag levels and the factor VIII:C/VWF:Ag ratio
in population-controls and in patients with different types of VWD mutations.
The factor VIII:C and VWF:Ag levels are shown for easier Interpretation of
the ratios. Data shown are the means and Standard deviations. The number of
subjects (n) is shown below the figure. All = all population-controls; 0 =
controls with blood group 0; non-0 = controls with blood groups A, B, and
AB; 2A-1,2A-2,2B, 2N, null = heterozygotes for VWD type 2A (group l), 2A
(group 2), 2B, 2N and null mutations, respectively. Note: the patient data from
literature are a mixture of lU/dl and U/dl




n 131 26 63 42 29 15 12
Fig. 2 Factor V1II:C and VWF:Ag levels and the factor VIH:C/VWF:Ag ratio
in heterozygotes for VWF nul l alleles and in patienls with VWD type 2N
mutalions. Data shown are the means and .Standard deviations. The number of
subjects (n) is shown below the figure. All = all heterozygotes for VWF null
alleles; 0-30, 31-60, >60 = heterozygotes for VWF null alleles categorized by
the level of VWF:Ag. 2N = heterozygotes for VWD type 2N mutations; 2N/2N
= homozygotes for VWD type 2N mutations; 2N/null = compound heterozygo-
tes for VWD type 2N and null mutations. Note: the patient data from literature
are a mixture of lU/dl and U/dl
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Residts on Subtypes 2A, 2B, and 2N
The type 2A mutations. in this case of the forme: subtype IIA, were
analyzed according to their respective pathogenic mechanism: group l
mutations with impaired intracellular transport and decreased secretion
of VWF, and group 2 mutations with normal synthesis and secretion but
increased susceptibility to extracellular proteolysis (28). In type 2A
group l the factor VIII:C/VWF:Ag ratio was 1.72, whereas in type 2A
group 2 mutations the ratio was l .22. As the VWF:Ag level in type 2A
group l mutations was lower than in group 2 (although this difference
is not statistically significant, Fig. 1) it cannot be excluded that the
increased factor VIII:C/VWF:Ag ratio in group l may simply reflect
the effect of low VWF level on the ratio (äs observed in the hetero-
zygotes for null alleles). Stratifying for VWF:Ag level in type 2A pa-
tients was not possible due to the limited number of individuals.
In heterozygotes for type 2B and 2N VWD mutations the ratio was
approximately one and not significantly different from the ratio in
normal controls. The factor VIII:C/VWF:Ag ratio was clearly reduced
in homozygotes for type 2N mutations (0.24) and in compound hetero-
zygotes for a 2N mutation and a null allele (0.43). No data were avail-
able on ABO blood group in types 2A and 2B, and no effect was seen
on the ratio in type 2N. Furthermore, no influence of sex was observed
on the factor VIII:C/VWF:Ag ratio in types 2A, 2B, and 2N.
Discussion
Decreased Secretion of VWF is Associated with Increased Ratio
When VWF is low due to a defect in its biosynthesis that results in
reduced secretion, the factor VIII:C/VWF:Ag ratio is increased. Null
alleles are the best model for a defect of synthesis. Heterozygotes were
found to have a ratio of 2.06 (Fig. 1). This observation was already
done many years ago in obligatory heterozygotes in families with type
3 VWD (3). When the group of null alleles was analyzed for different
strata of antigen levels the lowest levels were associated with the
highest factor VIII:C/VWF:Ag ratio (Fig. 2). The relation between
reduced synthesis and an increased factor VIII:C/VWF:Ag ratio was
also supported by another category of mutations associated with
decreased VWF secretion: type 2A group l mutations, characterized by
impaired intracellular transport and decreased secretion of VWF, were
associated with an increased ratio of 1.72. Although the number of
individuals that could be analyzed for this type of mutations was small,
the ratio was significantly increased compared to the normal controls
(Fig. 1).
How can we explain the increased factor VIII:C/VWF:Ag ratio
associated with reduced VWF secretion? Since VWF contains an
excess of unoccupied factor VIII binding sites, all factor VIII that is
synthesized will be bound by VWF. A reduction of VWF by 50% (äs
for example in heterozygotes for a null allele) consequently results in
an increase of the factor VIII:C/VWF:Ag ratio by two. When VWF:Ag
is further reduced, well below the level of 50%, the contribution of
circulating unbound factor VIII becomes more important and leads to a
further increase of the ratio at very low levels of the VWF:Ag. These
same mechanisms may explain why heterozygotes for type 2N muta-
tions show a factor VIII:C/VWF:Ag ratio of one despite the reduced
binding affinity for factor VIII that would predict a decreased ratio
(Figs. 1-2). Heterozygotes for 2N mutations have on average 50%
normal VWF subunits and 50% VWF subunits with reduced to absent
factor VIII binding affinity. As was shown for heterozygotes of null
alleles, 50% VWF can bind all factor VIII, and thus in general the ratio
is not reduced in heterozygotes for type 2N. Homozygotes for 2N
mutations only have mutant VWF subunits with low factor VIII
affinity and thus show a strongly reduced ratio (Fig. 2). The compound
heterozygotes for a type 2N mutation and a null allele, have a factor
VIII:C/VWF:Ag ratio that is twice äs high äs in the homozygotes for
2N mutations äs a result of the lower VWF:Ag level.
Increased Clearance of VWF Is Associated with a Ratio ofOne
When VWF is low due to a defect resulting in increased clearance of
VWF from the circulation the factor VIII:C/VWF:Ag ratio remains
unchanged, i.e. one. In type 2B VWD the clearance of VWF is in-
creased due to a higher affinity for platelet glycoprotein Ib resulting in
lower VWF:Ag levels and loss of high molecular weight multimers.
The factor VIII:C/VWF:Ag ratio in type 2B VWD patients was found
not to be different from normal controls (Fig. 1). Type 2A patients
belonging to group 2 have an increased clearance of VWF due to
enhanced susceptibility to extracellular proteolysis and were also found
to have a ratio dose to one (Fig. l). Furthermore, VWF levels are lower
in carriers of blood group 0 presumably due to increased clearance of
VWF (74). Even though the VWF:Ag levels are significantly lower in
blood group 0 than non-0 individuals the ratio of factor
VIII:C/VWF:Ag equals one in both groups of controls (Fig. 1).
Why does the factor VHI:C/VWF:Ag ratio remains unchanged when
VWF is reduced due to an increase of clearance? When clearance is
increased most likely VWF and factor VIII are cleared from the
circulation äs a complex resulting in a concordant decrease of VWF and
factor VIII, not affecting the ratio.
Clinical Implications ofthe Factor VIII:C/VWF:Ag Ratio
The diagnosis of mild type l VWD is often difficult due to the wide
normal ränge for VWF:Ag. The factor VIII:C/VWF:Ag ratio could help
in the Interpretation of laboratory data. When a patient with a border-
line VWF:Ag level has an increased factor VIII:C/VWF:Ag ratio, this
may indicate a true defect, possibly a VWF null allele. When a border-
line VWF:Ag level is associated with a factor VIII:C/VWF:Ag ratio of
one this suggests increased clearance and may reflect the effect of
blood group 0 on the VWF:Ag level. The diagnostic applicability of
the ratio is, however, limited by the large Standard deviations. Some of
the variability may be due to the inter-laboratory Variation in this study,
which may be less if measurements are performed in one laboratory.
The factor VIII:C/VWF:Ag ratio may not only be of relevance in
VWD, but could also help to understand the pathophysiology of high
factor VIII levels that are associated with venous thrombosis (70,75).
The majority (74%) of individuals with high factor VIII levels (> 150
lU/dL) have a factor VIII/VWF ratio of about one (76). Our data
indicate that a ratio of one is a determinant of clearance and an increas-
ed ratio a determinant of synthesis. Therefore, one could hypothesize
that increased factor VIII levels, when associated with a factor
VIII/VWF ratio of one, are the result of decreased clearance of the
factor VIII-VWF complex, whereas increased synthesis of factor VIII
could be reflected by an increased factor VIII/VWF ratio.
From these data on the factor VIII:C/VWF:Ag ratio we conclude
that there is not always a concordant change of VWF and factor VIII.
The ratio depends on the mechanism that causes the VWF change.
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